Eraxis
(Anidulafungin)ApprovedSmall molecule
Anidulafungin is used to treat serious fungal infections, particularly in the bloodstream and other parts of the body. It works by stopping the growth of certain types of fungi that can cause life-threatening infections, especially in hospitalized patients with weakened immune systems.[2] Eraxis is currently approved and in use across 12 indications[4].[1]
Eraxis is one of 289 small molecule programs targeting Candidiasis, Invasive. It is currently in Approved.
12
Indications
23
Total Trials
0
Active Trials
288
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Eraxis
VVicuron Pharmaceuticals
Approved
Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Aspergillosis4 trials
Candidiasis4 trials
Candidemia2 trials
Intravenous Administration1 trial
Critically Ill Patients1 trial
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
Terminated·—·Phase 2·NCT00934934·61 enrolled
10 more indications
Liver Disease1 trial
Infection1 trial
Antimicrobial PK in Infants With Suspected or Confirmed Infection
Completed·—··NCT00491426·450 enrolled
Liver Transplant1 trial
Immunocompromised1 trial
Transplant Recipient1 trial
Regulatory
FDA Approval Timeline[5]
Feb 17, 2006
ERAXIS
NDA NDA021632
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eraxis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Anidulafungin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 1,3-Beta-Glucan Synthase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VVicuron Pharmaceuticals